Patchouli Oil Attenuates High Fat Diet-induced Non-alcoholic Hepatic Steatosis

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Nevertheless, no first-line therapy exists. Hepatic steatosis is the earliest stage of NAFLD, which is characterized by an accumulation of hepatic lipids. Patchouli oil (PO), which is isolated from the well-known Chinese herb named Pogostemon cablin (Blanco) Benth. (Lamiaceae), inhibits hepatic lipid accumulation effectively. However, its potential ability for the treatment of NAFLD had not been reported before. Thus, the objective of this study was to investigate the effectiveness of PO against hepatic steatosis and its underlying mechanisms. We used a high fat diet (HFD)-induced hepatic steatosis model of rats to estimate the effect of PO against NAFLD. Hematoxylin-eosin and oil red O staining were used to analyze the hepatic histopathological changes. ELISA, RT-qPCR, and Western blotting analysis were applied to evaluate the parameters for hepatic steatosis. Our results showed that PO significantly attenuated the lipid profiles and the serum enzymes, evidenced by quantitative and histopathological analyses. It also markedly down-regulated the expression of sterol regulatory element-binding protein 1 (SREPB-1c) with its downstream factors in de novo lipogenesis. And, likewise, in lipid export by very low-density lipoproteins (VLDL), related molecules were dramatically improved. Furthermore, PO observably normalized the aberrant peroxisome proliferator-activated receptor α (PPAR-α) signal in fatty acids oxidation. In conclusion, PO exerted a preventing effect against HFD-induced steatosis and might be due to decrease de novo lipogenesis, promote export of lipids, as well as owing to improve fatty acids oxidation.

Key words

non-alcoholic fatty liver disease - hepatic steatosis - patchouli oil - Pogostemon cablin - Lamiaceae

• References

• 1 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
• 2 Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686-690
• 3 Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008; 118: 829-838
• 4 Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014; 15: 6184-6223
• 5 Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2008; 14: 22-28
• 6 Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab 2011; 13: 692-702
• 7 Bahmani M, Mirhoseini M, Shirzad H, Sedighi M, Shahinfard N, Rafieian-Kopaei M. A review on promising natural agents effective on hyperlipidemia. J Evid Based Complementary Altern Med 2015; 20: 228-238
• 8 Chen MW, Zhang JM, Lai YF, Wang SP, Li P, Xiao J, Fu CM, Hu H, Wang YT. Analysis of Pogostemon cablin from pharmaceutical research to market performances. Expert Opin Investig Drugs 2013; 22: 245-257
• 9 Lin RF, Feng XX, Li CW, Zhang XJ, Yu XT, Zhou JY, Zhang X, Xie YL, Su ZR, Zhan JYX. Prevention of UV radiation-induced cutaneous photoaging in mice by topical administration of patchouli oil. J Ethnopharmacol 2014; 154: 408-418
• 10 Zhang Z, Chen X, Chen H, Wang L, Liang J, Luo D, Liu Y, Yang H, Li Y, Xie J, Su Z. Anti-inflammatory activity of beta-patchoulene isolated from patchouli oil in mice. Eur J Pharmacol 2016; 781: 229-238
• 11 Huang QH, Wu X, Chen XH, Wu JZ, Su ZR, Liang JL, Li YC, Lai XP, Chen JN, Liu YH. Patchouli oil isolated from the leaves of Pogostemon cablin ameliorates ethanol-induced acute liver injury in rats via inhibition of oxidative stress and lipid accumulation. RSC Adv 2018; 8: 24399-24410
• 12 Ferramosca A, Zara V. Modulation of hepatic steatosis by dietary fatty acids. World J Gastroenterol 2014; 20: 1746-1755
• 13 Nguyen P, Leray V, Diez M, Serisier S, Blocʼh JL, Siliart B, Dumon H. Liver lipid metabolism. J Anim Physiol Anim Nutr 2008; 92: 272-283
• 14 Mendez-Sanchez N, Arrese M, Zamora-Valdes D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 2007; 27: 423-433
• 15 Strable MS, Ntambi JM. Genetic control of de novo lipogenesis: role in diet-induced obesity. Crit Rev Biochem Mol Biol 2010; 45: 199-214
• 16 Osborne TF. Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J Biol Chem 2000; 275: 32379-32382
• 17 Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008; 134: 424-431
• 18 Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009; 48: 1-26
• 19 Zhang D, Yan Y, Tian H, Jiang G, Li X, Liu W. Resveratrol supplementation improves lipid and glucose metabolism in high-fat diet-fed blunt snout bream. Fish Physiol Biochem 2018; 44: 163-173
• 20 Chiu CY, Wang LP, Liu SH, Chiang MT. Fish oil supplementation alleviates the altered lipid homeostasis in blood, liver, and adipose tissues in high-fat diet-fed rats. J Agric Food Chem 2018; 66: 4118-4128
• 21 Geldenhuys WJ, Caporoso J, Leeper TC, Lee YK, Lin L, Darvesh AS, Sadana P. Structure-activity and in vivo evaluation of a novel lipoprotein lipase (LPL) activator. Bioorg Med Chem Lett 2017; 27: 303-308
• 22 Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006; 290: G852-G858
• 23 Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quinones L, Varela N, Contreras J, Lazarte R, Csendes A, Rojas J, Maluenda F, Burdiles P, Diaz JC, Smok G, Thielemann L, Poniachik J. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci 2004; 106: 261-268
• 24 Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011; 412: 1297-1305
• 25 Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014; 2014: 360438
• 26 Ucar F, Sezer S, Erdogan S, Akyol S, Armutcu F, Akyol O. The relationship between oxidative stress and nonalcoholic fatty liver disease: its effects on the development of nonalcoholic steatohepatitis. Redox Rep 2013; 18: 127-133
• 27 Van De Wier B, Koek GH, Bast A, Haenen GR. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Crit Rev Food Sci Nutr 2017; 57: 834-855
• 28 Feng XX, Yu XT, Li WJ, Kong SZ, Liu YH, Zhang X, Xian YF, Zhang XJ, Su ZR, Lin ZX. Effects of topical application of patchouli alcohol on the UV-induced skin photoaging in mice. Eur J Pharm Sci 2014; 63: 113-123
• 29 Yu JL, Zhang XS, Xue X, Wang RM. Patchouli alcohol protects against lipopolysaccharide-induced acute lung injury in mice. J Surg Res 2015; 194: 537-543
• 30 Chalouati H, Ben Sâad MM, Payrastre L. Hepatoprotective effects of vitamin E against hexachlorobenzene-induced hepatotoxicity and oxidative stress in rats: histological, biochimical and antioxidant status changes. Toxicol Mech Methods 2019; 29: 18-25
• 31 Chen Z, Liu F, Zheng N, Guo M, Bao L, Zhan Y, Zhang M, Zhao Y, Guo W, Ding G. Wuzhi capsule (Schisandra Sphenanthera extract) attenuates liver steatosis and inflammation during non-alcoholic fatty liver disease development. Biomed Pharmacother 2019; 110: 285-293
• 32 Duan X, Meng Q, Wang C, Liu Z, Sun H, Huo X, Sun P, Ma X, Peng J, Liu K. Effects of calycosin against high-fat diet-induced nonalcoholic fatty liver disease in mice. J Gastroenterol Hepatol 2018; 33: 533-542